R-Mini-CHOP plus ibrutinib demonstrates promising PFS in newly diagnosed DLBCL

According to primary analysis data from the Australasian Leukaemia & Lymphoma Group NHL29 study presented during the 2021 American Society of Hematology Annual Meeting, older patients with newly diagnosed DLBCL who received ibrutinib plus R-mini-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone experienced improved outcomes compared with those patients who received R-mini-CHOP only. Two-year progression-free survival with the addition of ibrutinib was 60% (95% CI, 49%-72%; P < .03), versus 47% in the R-mini-CHOP alone group.